top of page
ICYMI: IGT Chair Erik Paulsen and Scientific, Academic and Medical Council Chair Donna M. Christensen on the Future of Gene Therapy
IGT leaders recently penned a piece exploring the strides being made in gene therapy and highlighting the ongoing challenges that must be...
The Federal Newborn Screening Program at a Crossroads
As Newborn Screening Awareness Month concludes, IGT applauds the tireless work of advocates who dedicate themselves 365 days of the year...
What Newborn Screening Really Means in the Sickle Cell Disease Community and Beyond
Author: Andrea Matthews, Founder, Children’s Sickle Cell Foundation, Inc.  Newborn screening (NBS) is an important public health measure...
IGT Patient Advocacy Advisory Council Members Recognize Newborn Screening Awareness Month
Newborn screening is critical to ensure faster access to treatment and cures for genetic conditions. This September, IGT is recognizing...
IGT Joins House Budget Committee Health Care Task Force Roundtable on Cell and Gene Therapies
On Friday, June 28, the House Budget Committee Health Care Task Force hosted a roundtable entitled, “Paying for 21st Century Cures:...
IGT, ARM Congressional Briefing Highlights: MDRP Proposed Changes Threaten Patient Access to Care
The Centers for Medicare and Medicaid Services (CMS) may soon finalize proposed changes to the Medicaid Drug Rebate Program (MDRP) that,...
Congressional Briefing: Realizing the Promise of Gene Therapy: Protecting Patients & Innovation
On May 9, the Institute for Gene Therapy (IGT), along with the Alliance for Regenerative Medicine (ARM), held a Congressional briefing...
IGT Statement on Senate Introduction of the MVP Act
Today, Senators Markwayne Mullin (R-OK), Kyrsten Sinema (AZ), Tim Scott (SC), and Maggie Hassan (NH) introduced the Senate companion to...
Health Care’s Genetic and Cellular Transformation Must Benefit All Patients in Need
By Regina Hartfield, President and CEO, Sickle Cell Disease Association of America, Inc. This year, we celebrate a landmark step forward...
IGT Responds to HRSA RFI on Nomination and Evidence-Based Review Process of the Advisory Committee on Heritable Disorders in Newborns and Children
Last week, the Institute for Gene Therapies (IGT) sent a response to the Health Resources and Services Administration (HRSA) Request for...
bottom of page